These findings suggest that Flt3 may be a promising therapeutic target for cardiac remodeling and heart failure since protecting L-OPA1 from processing can efficiently reduce mitochondrial network fragmentation and apoptosis. This evidence concerns the gene OPA1 and heart failure.